These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
548 related articles for article (PubMed ID: 25905947)
1. Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging. Chirindel A; Alluri KC; Chaudhry MA; Wahl RL; Pawlik TM; Herman JM; Subramaniam RM AJR Am J Roentgenol; 2015 May; 204(5):1093-9. PubMed ID: 25905947 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Chen HH; Chiu NT; Su WC; Guo HR; Lee BF Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
4. FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer. Taghipour M; Wray R; Sheikhbahaei S; Wright JL; Subramaniam RM AJR Am J Roentgenol; 2016 Apr; 206(4):846-55. PubMed ID: 27003053 [TBL] [Abstract][Full Text] [Related]
5. 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction. Sheikhbahaei S; Wray R; Young B; Mena E; Taghipour M; Rahmim A; Subramaniam RM Nucl Med Commun; 2016 Mar; 37(3):231-8. PubMed ID: 26575392 [TBL] [Abstract][Full Text] [Related]
6. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. Dibble EH; Alvarez AC; Truong MT; Mercier G; Cook EF; Subramaniam RM J Nucl Med; 2012 May; 53(5):709-15. PubMed ID: 22492732 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas. Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902 [TBL] [Abstract][Full Text] [Related]
8. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. Satoh Y; Onishi H; Nambu A; Araki T Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640 [TBL] [Abstract][Full Text] [Related]
9. The Significance of FDG PET/CT-Derived Parameters in Determining Prognosis of Cases with Pancreatic Adenocarcinoma: A Prospective Study. Mokhtar HM; Youssef A; Naguib TM; Magdy AA; Salama SA; Kabel AM; Sabry NM Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013494 [TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods. Mena E; Sheikhbahaei S; Taghipour M; Jha AK; Vicente E; Xiao J; Subramaniam RM Clin Nucl Med; 2017 Jan; 42(1):e16-e21. PubMed ID: 27819858 [TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer. Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649 [TBL] [Abstract][Full Text] [Related]
12. JOURNAL CLUB: Value of Quantitative FDG PET/CT Volumetric Biomarkers in Recurrent Colorectal Cancer Patient Survival. Marcus C; Wray R; Taghipour M; Marashdeh W; Ahn SJ; Mena E; Subramaniam RM AJR Am J Roentgenol; 2016 Aug; 207(2):257-65. PubMed ID: 27447341 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis. Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018 [TBL] [Abstract][Full Text] [Related]
14. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma. Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646 [TBL] [Abstract][Full Text] [Related]
15. The Volume-metabolic Combined Parameters from (18)F-FDG PET/CT May Help Predict the Outcomes of Cervical Carcinoma. Sun Y; Lu P; Yu L Acad Radiol; 2016 May; 23(5):605-10. PubMed ID: 26853968 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877 [TBL] [Abstract][Full Text] [Related]
17. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma. Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy. Choi HJ; Lee JW; Kang B; Song SY; Lee JD; Lee JH Yonsei Med J; 2014 Nov; 55(6):1498-506. PubMed ID: 25323885 [TBL] [Abstract][Full Text] [Related]
19. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis. Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of preoperative metabolic tumor volume measured by ¹⁸F-FDG PET/CT and MRI in patients with endometrial cancer. Chung HH; Lee I; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ Gynecol Oncol; 2013 Sep; 130(3):446-51. PubMed ID: 23791826 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]